Loading...
Loading...
ALLR| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 1.0K |
| Gross Profit | -1.0K |
| Operating Expense | 3,370.0K |
| Operating I/L | -3,371.0K |
| Other Income/Expense | 1,742.0K |
| Interest Income | 53.0K |
| Pretax | -1,629.0K |
| Income Tax Expense | 0.0K |
| Net Income/Loss | -1,629.0K |
Allarity Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in developing oncology therapeutics. The company's primary focus is on utilizing drug-specific companion diagnostics created by its drug response predictor technology. Its drug candidates, including Stenoparib, Dovitinib, IXEMPRA, LiPlaCis, and 2X-111, are in various stages of clinical trials for the treatment of ovarian cancer, renal cell carcinoma, metastatic breast cancer, and glioblastoma multiforme. Allarity Therapeutics generates revenue through the development and potential commercialization of these innovative oncology therapeutics, leveraging its proprietary companion diagnostics to target specific patient populations.
